3 results match your criteria: "Medicines Discovery Centre[Affiliation]"

In Silico Adjuvant Design and Validation.

Methods Mol Biol

January 2018

Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France.

Adjuvants are substances that boost the protective immune response to vaccine antigens. The majority of known adjuvants have been identified through the use of empirical approaches. Our aim was to identify novel adjuvants with well-defined cellular and molecular mechanisms by combining a knowledge of immunoregulatory mechanisms with an in silico approach.

View Article and Find Full Text PDF

Targeting CCR4 as an emerging strategy for cancer therapy and vaccines.

Trends Pharmacol Sci

April 2014

Epinova Discovery Performance Unit, Immuno-inflammation Therapeutic Area, GlaxoSmithKline, Medicines Discovery Centre, SG1 2NY, Stevenage, UK.

View Article and Find Full Text PDF

Modulation of T-cell function by type I interferon.

Immunol Cell Biol

May 2012

Epinova Discovery Performance Unit, Immuno-inflammation Therapeutic Area, GlaxoSmithKline, Medicines Discovery Centre, Stevenage, UK.

Production of type I interferon (IFN-α/β) is a common cellular response to virus infection. IFN-α/β has a dual role in combating infection, triggering innate antiviral mechanisms and stimulating the generation of an adaptive immune response. This review focuses on the effects of IFN-α/β on one particular immune cell type, the T cell, and the impact of IFN-α/β-mediated signalling in T cells on the immune response.

View Article and Find Full Text PDF